Krystal Biotech, Inc.
KRYS
$306.29
-$10.01-3.17%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 417.30M | 389.13M | 373.16M | 359.21M | 333.45M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 417.30M | 389.13M | 373.16M | 359.21M | 333.45M |
| Cost of Revenue | 24.34M | 23.05M | 21.41M | 23.83M | 22.67M |
| Gross Profit | 392.96M | 366.08M | 351.76M | 335.38M | 310.78M |
| SG&A Expenses | 155.20M | 146.83M | 136.67M | 127.77M | 120.23M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 238.66M | 227.93M | 214.86M | 207.30M | 199.78M |
| Operating Income | 178.64M | 161.20M | 158.31M | 151.91M | 133.67M |
| Income Before Tax | 207.32M | 189.47M | 186.95M | 168.75M | 138.02M |
| Income Tax Expenses | -17.72M | -15.36M | -11.96M | 22.03M | 14.06M |
| Earnings from Continuing Operations | 225.03 | 204.83 | 198.91 | 146.73 | 123.96 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 225.03M | 204.83M | 198.91M | 146.73M | 123.96M |
| EBIT | 178.64M | 161.20M | 158.31M | 151.91M | 133.67M |
| EBITDA | 180.34M | 162.79M | 159.60M | 153.24M | 135.98M |
| EPS Basic | 7.74 | 7.07 | 6.89 | 5.09 | 4.31 |
| Normalized Basic EPS | 4.46 | 4.09 | 4.05 | 3.93 | 3.55 |
| EPS Diluted | 7.48 | 6.85 | 6.68 | 4.93 | 4.17 |
| Normalized Diluted EPS | 4.30 | 3.96 | 3.92 | 3.80 | 3.41 |
| Average Basic Shares Outstanding | 116.24M | 115.77M | 115.43M | 115.20M | 114.88M |
| Average Diluted Shares Outstanding | 120.34M | 119.70M | 119.34M | 119.41M | 119.29M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |